For two decades, LEMS patients have received a drug for free from Jacobus Pharmaceutical under the Food and Drug Administration’s compassionate use program. Recently, Catalyst Parmaceuticals bought the drug and announced to investors it would set the list price at $375,000 per year. Rebecca, one of the many patients who does not know how she will afford it, talked to Sen. Bernie Sanders about what's going on.....
No comments:
Post a Comment